Furthermore, Bright Minds was highlighted by TD Cowen analyst Joseph Thome as a key player in the biotech sector, with its Phase II BMB-101 data in absence seizures listed as a significant catalyst ...
Bright Minds (DRUG) Biosciences announced positive and significant topline results from its Phase 2 BREAKTHROUGH clinical trial evaluating BMB-101, a selective 5-HT2C biased agonist, in adult patients ...
Shares of Bright Minds Biosciences rose after the company released positive topline results from its phase two trial of a treatment for patients with drug-resistant Absence Seizures and Developmental ...
Absence: 73.1% median reduction in the number of absence seizure ≥3s, p = 0.012 DEE: 63.3% median reduction in major motor seizures REM sleep improvement in patients with Absence Seizures: mean 90% ...
The Phase 2 open-label, multicenter study evaluated safety, tolerability and efficacy of BMB-101 in adults with drug-resistant Absence Seizures and DEE. A total of 24 patients were enrolled, exceeding ...
NEW YORK, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (Nasdaq: DRUG) (“Bright Minds” or the “Company”), a clinical-stage biotechnology company focused on developing ...
Epilepsy is not a one size fits all condition and there are a few tell tale signs that parents could miss, said Dr Jonathan Redelinghuys. In the Middle Ages, epilepsy was blamed on demonic possession.
(MENAFN- GlobeNewsWire - Nasdaq) – Conference Call and Live Webcast at 8AM ET – NEW YORK, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results